Although immunotherapy, such as PD1/PD-L1 immune checkpoint inhibitors (ICIs), has been shown to improve the survival of advanced NSCLC patients without driver mutations (30), the survival benefit of immunotherapy is still very limited for advanced EGFR-mutated NSCLC patients (29, 30). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.